Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
pH maintenance, Spermicide, Microbicide Lubricant More
Novel Dual Chamber Dispenser with polycarbonate and stainless steel components for accurate Rx dosing. More
Herpclair is a topical composition based on extracts of plants suitably selected to ensure anti-herpes type 1 activity. More
A novel selective antimicrobial peptide based on human LL-37 by D-amino acid incorporation. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
Filtrum adsorbs in the gastro-intestinal tract a wide variety of toxins, pathogenic bacteria and its metabolites thus neutralizing its concentration which results in elimination of the corresponding symptoms and recovery period. More
Novel use of amine-borane compounds for the treatment of medical conditions associated with microorganisms.These compounds are an answer to the big search for antimicrobial agents to combat the development of resistance to current medications More
Novel glutathione derivatives and their use in antiviral therapy More
A novel cyclized histatin-based peptide DB2-121 that is a potent new antifungal agent active against the clinically important Candida albicans and a number of other organisms. More
We have modified a gene from human RSV which results in the generation of neutralising antibodies and a long-lived and robust protective response against RSV infection More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Candida
- Cytomegalovirus
- Ebola virus
- Escherichia coli
- Haemophilus influenzae
- Hantavirus
- Helicobacter pylori
- Herpes simplex virus
- Human B19 parvovirus
- Human papilloma virus
- Parainfluenza virus (Type 3)
- Pertussis
- Respiratory syncytial virus RSV
- Rubella
- Salmonella
- Varicella-zoster
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us